Tesamorelin Dosage Guide
Complete guide to Tesamorelin dosing protocols, administration methods, and safety considerations for research purposes.
Dosage Overview
Dose per Injection
2 mg
Frequency
Once per day
Route
subcutaneous
Cycle Length
8–52 weeks
Reconstitution
Vial Size
2 mg
BAC Water
2.0 ml
Concentration
1,000 mcg/ml
Detailed Dosage Information
FDA-approved dose
2mg administered subcutaneously once daily.
Research protocols may use various dosing schedules.
Administration Method
Subcutaneous injection into the abdomen. Rotate injection sites. Best administered at the same time daily, preferably in the evening.
Research Use Only: All dosage ranges and calculations are derived from published research literature and are provided for educational purposes. These are not prescriptions or medical recommendations. Consult a healthcare professional before any use.
Concentration: 1 mg/ml
Volume to inject: 2.000 ml
Syringe units: 200.0 units — exceeds 1 ml syringe, split into multiple injections
U-100 insulin syringe (100 units = 1 ml). Verify dose with a clinician before injecting.
Pre-filled with Tesamorelin defaults. Adjust values as needed.
Side Effects to Monitor
Common side effects include injection site reactions (erythema, pruritus), joint pain, peripheral edema, and muscle pain. May cause elevated blood glucose.
Safety Considerations & Risks
Contraindicated in patients with active malignancy, hypersensitivity to GHRH, or during pregnancy. May affect glucose metabolism. Requires monitoring of IGF-1 levels.